# Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

> **NCT06884254** · PHASE3 · WITHDRAWN · sponsor: **EirGenix, Inc.**

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** EG1206A
- **DRUG:** Perjeta

## Key facts

- **NCT ID:** NCT06884254
- **Lead sponsor:** EirGenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05
- **Primary completion:** 2026-11
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Following SA from both the US FDA and the EMA, EirGenix, Inc. has decided to streamline the clinical-development program for EG1206A (biosimilar to Perjeta). EirGenix has concluded that the continuation of the study in no longer necessary.
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06884254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06884254, "Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06884254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*